First-in-human implantation of a fully bioabsorbable drug-eluting stent: The BVS poly-L-lactic acid everolimus-eluting coronary stent

Catheterization and Cardiovascular Interventions

Volumn 69, Issue 1, 2007, Pages 128-131

  Ormiston, John A ^a,b   Webster, Mark W I ^a   Armstrong, Guy ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b Mercy Hospital   (New Zealand)

Author keywords

Bioabsorbable; Drug elution; Internal hyperplasia; Polyactic acid; Stent

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; GLYCERYL TRINITRATE; HIRULOG; POLYLACTIC ACID;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BIODEGRADABLE IMPLANT; CASE REPORT; CORONARY STENT; DRUG ELUTING STENT; HEART EJECTION FRACTION; HEART LEFT VENTRICLE CONTRACTILITY; HUMAN; MALE; NEW ZEALAND; ST SEGMENT DEPRESSION;

ABSORBABLE IMPLANTS; ANGINA PECTORIS; CORONARY ANGIOGRAPHY; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LACTIC ACID; MALE; MIDDLE AGED; POLYMERS; SIROLIMUS; STENTS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 33846012863     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.20895     Document Type: Article

References (8)

1. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Mokihara S, Uehata H. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation 2000;102:399-404.
2. Tamai H. Biodegradable stents. Four year follow-up. Paper presented at TCT 2004. Washington, DC: 2004.
3. Absorb Trial Investigator Brochure, Abbott Vascular, Santa Clara, CA.
4. Serruys PW, Ong TL, Piek JJ, Neumann F-J, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase L, Thuesen L, Hamm C, Otto-Terlouw PC. A randomized comparison of a durable polymer everolimus eluting stent with a bare metal coronary sent: The SPIRIT first trial. Eurointervention 2005;1:58-65.
5. Tsuchida K, Piek JJ, Neumann F-J, van der Giessen WJ, Wiemer M, Zeiher AM, Grube E, Haase J, Thuesen L, Hamm C, Veldhof S, Dorange C, Serruys PW. One year results of a durable polymer everolimus eluting stent in de novo coronary narrowings. The SPIRIT first trial. Eurointervention 2005;1:266-272.
6. Van der Glessen WJ, Lincoff AM, Schwartz, RS, van Beusekom HM, Serruys PW, Holmes DR, Ellis SG. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradablel polymers in porcine coronary arteries. Circulation 1996;94:1690-1697.
7. Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ, Grube E. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004;109:2168-2171.
8. Ormiston JA, Webster MWI, Ruygrok PN, Meredith IT, Ardill J, Buller C, Ricci DR, Chan C, Devlin GP, Stewart JT, Penn I, Price S, Webber B, West T. For the Stella Trial Investigators. Six-month angiographic and 12-month clinical follow-up of Multilink long (25 to 35 mm) stents for long coronary narrowings in patients with angina pectoris. Am J Cardiol 2002;90:222-226.